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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with myeloablative conditioning is associated
with a 10%-40% risk of day þ100 transplantation-related mortality (TRM). We evaluated the feasibility and
safety of reduced-toxicity conditioning and allo-HSCT in 100 consecutive children and adolescent recipients
(mean age, 9.2  6.8 years). The mean duration of follow-up was 1278  1042 days. Fifty patients had
malignant disease. The median time to neutrophil recovery was 18 days, and the median time to platelet
recovery was 43 days. Median donor chimerism in engrafted patients was 98% on day þ100 and 98% on
day þ365. The cumulative incidence of acute graft-versus-host disease (GVHD) was 20% (95% conﬁdence
interval [CI], 12.1%-27.9%), and that of chronic GVHD was 13.5% (95% CI, 6.6%-20.4%). TRM was 3% (95% CI,
0%-6.4%) by day þ100 and 13.6% (95% CI, 6.7%-20.5%) for the entire study period. The incidence of primary graft
failure (PGF) was 16% overall, 31.4% after umbilical cord blood transplantation (UCBT), and 0% after allo-HSCT
with matched unrelated or matched sibling donors (P < .0001). The incidence of PGF in UCBT recipients was
46.7% (14 of 30) in chemotherapy-naive recipients, versus 9.5% (2 of 21) in nonechemotherapy-naive recipients
(P ¼ .019). Five-year event-free survival was 59.5%  5%, and 5-year overall survival was 72.9%  5%. Only PGF
and poor-risk disease status were signiﬁcantly associated with decreased overall survival (P ¼ .03). Reduced-
toxicity conditioning allo-HSCT in pediatric recipients is associated with low TRM; however, chemotherapy-
naive UCBT recipients have a signiﬁcantly higher incidence of PGF.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) with myeloablative conditioning (MAC) is a well-
established curative therapy for children and adults with
various malignant and nonmalignant hematologic disorders,
primary immunodeﬁciencies (PID), and metabolic diseases
[1]. Reduced-toxicity conditioning (RTC) has emerged as an
alternative to traditional MAC. RTC is deﬁned as a regimen
associated with various degrees of myeloablation, but with
decreased toxicity secondary to conditioning compared with
traditional MAC [2,3]. The purpose of RTC is to decrease
transplantation-related mortality (TRM) while establishingat the American Society of Blood and
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Children with malignant and nonmalignant diseases who
receiveMAC allo-HSCTexperience both short-term and long-
term late complications [4]. TRM after MAC allo-HSCT
depends on various factors, including performance status,
disease type, disease status, allogeneic donor source, and
quantity of committed stem progenitor cells infused [5-7].
According to recent Center for International Blood and
Marrow Transplant Research analyses, the day þ100
mortality rate is 5%-20% for patients with malignant and
nonmalignant diseases after MAC HLA-matched sibling
donor (MSD) allo-HSCT and 10%-40% after unrelated donor
allo-HSCT [8]. In another recent study of children with
leukemia and myelodysplastic syndrome (MDS), Shaw et al.
[9] reported a cumulative 3-year incidence of TRM after MAC
allo-HSCT was 10% for MSD graft recipients, compared with
27% for matched unrelated donor (MUD) graft recipients.
TRM in children after MAC and umbilical cord blood (UBC)
transplantation (UCBT) is signiﬁcantly higher, ranging from
20% to 52% [6,10-12].Transplantation.
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after MAC allo-HSCT in 6691 patients who were free of their
original disease for at least 2 years after transplantation.
Numerous patients died of other secondary complications,
including graft-versus-host disease (GVHD; 31%), infection
(6%), secondary malignancies (6%), and organ failure (6%).
More recently, Sun et al. [13] reported a 59% 10-year cumu-
lative incidence of a chronic health condition and a 35%
10-year cumulative incidence of a severe life-threatening
condition or death from a chronic health condition in MAC
allo-HSCT recipients. Surviving MAC allo-HSCT recipients
were twice as likely as siblings to develop a chronic condition
and 3.5 timesmore likely to develop a severe/life-threatening
condition [13].
These potential short-term and long-term complications
sometimes factor strongly in thedecisiononwhetherornot to
proceed with curative-intent therapy, especially in children
with nonmalignant diseases. The feasibility of performing
RTC allo-HSCT in medically inﬁrm children has been recently
reported by Pulsipher et al. [14] on behalf of the Pediatric
Blood and Marrow Transplant Consortium. Jacobsohn et al.
[15] also demonstrated the feasibility of RTC allo-HSCT in
a small group of children with nonmalignant disorders who
were also eligible for conventional MAC allo-HSCT.
Whether a select group of children receiving RTC allo-
HSCT will beneﬁt from a reduced risk of disease reoccur-
rence and at the same time a reduced risk of short-term and
long-term complications remains to be determined. In the
present single-center study, we examined the risk factors
associated with TRM, primary graft failure (PGF), and overall
survival (OS) in the ﬁrst 100 consecutive children and
adolescents who underwent RTC allo-HSCT for malignant
and nonmalignant diseases at our institution.
PATIENTS AND METHODS
The cohort for this analysis comprised 100 consecutive children and
adolescents who underwent RTC allo-HSCT at the New York-Presbyterian
Morgan Stanley Children’s Hospital between January 2001 and October
2010. Pilot data for a small number of patients receiving RTC with shorter
follow-up have been reported [16,17]. The ﬁrst pilot study [16] consisted of
21 patients, with 14 UCBT recipients, 3MSC allo-HSCT recipients, and 4MUD
allo-HSCT recipients. In our second report, we described 21 pediatric RTC
UCBT recipients.
Indications for transplantation included a variety of malignant and
nonmalignant conditions. Allogeneic stem cell sources included bone
marrow (BM), peripheral blood stem cells (PBSCs), and UBC. All patients
were on a clinical research protocol for allo-HSCT approved by the Institu-
tional Review Board at Columbia University Medical Center, and all research
protocols were in compliance with the Declaration of Helsinki. This retro-
spective study was separately approved by the Institutional Review Board of
Columbia University Medical Center.
Eligibility
Patients age 22 years with both malignant and nonmalignant disorders
with or without previous comorbidities were eligible for RTC allo-HSCT.
There were no open trials for RTC allo-HSCT in children with acute
lymphoblastic leukemia. Adequate pretransplantation organ function was
deﬁned by organ system. Adequate renal function was deﬁned as serum
creatinine 2 times the normal value, creatinine clearance 40 mL/min/m2,
or a radioisotope glomerular ﬁltration rate (GFR) >60 mL/min/1.73 m2 or an
equivalent GFR as determined by the institution’s normal range. Adequate
liver function was deﬁned as total bilirubin <2 times normal and a serum
glutamic oxaloacetic transaminase (aspartate aminotransferase) or serum
glutamic pyruvate transaminase (alanine aminotransferase) value <5 times
normal. Adequate cardiac function was deﬁned as a shortening fraction of
>27% detected by echocardiography, or an ejection fraction of >47% by
radionuclide angiography or echocardiography. Adequate pulmonary func-
tionwas deﬁned as diffusing capacity of the lung for carbonmonoxide>40%
by pulmonary function testing or, in children who are uncooperative, no
evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry
reading of >94% in room air. A Lansky or Karnofsky performance score >40
was required for eligibility.Exclusion Criteria
Patients who received CD34-selected cells and T celledepleted trans-
plants, haploidentical allo-HSCT, double UCBT, or a second RTC allo-HSCT as
a rescue for previous graft failure after the ﬁrst RTC allo-HSCT were excluded
from our analyses.
HLA Typing and Stem Cell Source
HLA-A, -B (antigen match by intermediate resolution), -C, -DRB1, and
-DQB1 (allele match by high resolution) typing was determined by
hybridization of PCR-ampliﬁed DNA with sequence-speciﬁc oligonucleotide
probes, as described previously [16]. Conﬁrmatory typing was performed at
Columbia University Medical Center. The criteria for graft matching included
at least 4-6/6 loci for UBC and at least 8/10 loci for unrelated donor PBSCs/
BM and 5-6/6 for MSD grafts. allo-HSCT was classiﬁed as HLA-mismatched
with 1 or 2 differences if disparities were detected in HLA-A and -B anti-
gens or in HLA-C, -DRB1, and -DQB1 alleles.
Conditioning Regimens
Speciﬁc conditioning regimens were protocol-driven and disease-
speciﬁc. For the present study, we combined 3 different regimens that
delivered lower chemotherapy doses than provided by the standard MAC
regimen or with a second alkylating agent replaced by ﬂudarabine. RTC
regimens included BFA (busulfan 6.4-8 mg/kg and ﬂudarabine 150 mg/m2,
with or without rabbit antithymocyte globulin [r-ATG] 8mg/kg; n¼ 45), BFC
(busulfan 12.8-16 mg/kg, ﬂudarabine 150-180 mg/m2, alemtuzumab 54 mg/
m2; n¼ 35), and FCA (cyclophosphamide 60 mg/kg and ﬂudarabine 150 mg/
m2 with or without r-ATG 8 mg/kg; n ¼ 20). RTC regimens in children with
malignant disease were restricted to those with acute myelogenous
leukemia (AML), chronic myelogenous leukemia (CML), lymphoma, and
neuroblastoma. Only patients who underwent UCBT and MUD allo-HSCT
received r-ATG. The majority of children with severe aplastic anemia, PID,
and leukodystrophies received cyclophosphamide 60 mg/kg þ ﬂudarabine
150 mg/m2. A regimen comprising busulfan 6.4-8 mg/kg þ ﬂudarabine 150-
180 mg/m2 was administered to childrenwith all malignant diseases except
CML, and a regimen consisting of busulfan 12.8-16 mg/kg, ﬂudarabine 180
mg/m2, þ alemtuzumab 54 mg/m2 was used in children at high risk of graft
failure, such as those with hemoglobinopathies and CML. Busulfan phar-
macokinetic studies were performed in children who received busulfan
12.8-16 mg/kg, as reported previously [3]. The target steady-state busulfan
concentration after the ﬁrst dose and subsequent doses was 600-900 ng/mL.
GVHD Prophylaxis and Grading
Acute GVHD (aGVHD) prophylaxis consisted of tacrolimus starting at
0.03 mg/kg/day as continuous i.v. infusion or 0.12 mg/kg orally twice a day,
with dosage adjustments to maintain blood levels between 5 and 20 ng/mL,
along with mycophenolate mofetil (MMF) 15-30 mg/kg every 6-12 hours
either orally or i.v., as described previously [18,19]. Tacrolimus was started
on the ﬁrst day of conditioning, and MMF was initiated on day þ1. Tacro-
limus andMMFwere tapered if grade II aGVHD developed between dayþ30
and dayþ60 in patients with malignant disease and by dayþ180 in patients
with nonmalignant disease [19]. aGVHD and chronic GHVD (cGVHD) were
graded according to the Seattle criteria [20]. Adult recipients of MUD allo-
HSCT also received methotrexate 15 mg/m2 administered i.v. on day þ1,
followed by 10 mg/m2 via slow i.v. push on days þ3, þ6, and þ11.
Engraftment and Donor Chimerism
Myeloid engraftment was deﬁned as an absolute neutrophil count (ANC)
of 500  109/L on the ﬁrst of 3 consecutive days. Platelet recovery was
deﬁned as the ﬁrst day of the 7 days on which the platelet count was 20 
109/L independent of platelet transfusion. Donor myeloid and/or lymphoid
chimerism was measured on days þ30, þ60, þ100, þ180, and þ365 post-
transplantation. Percent donor chimerism was determined by quantifying
ﬂuorescent-labeled PCR products from donor and recipient alleles at short
tandem repeat loci, as described previously [3,16]. Donor chimerism was
determined for whole blood and cell subsets as required by individual
disease protocols. Cell subsets were isolated using Miltenyi (Miltenyi Biotec,
Bisley, UK) magnetic separation.
Infection Prophylaxis and Supportive Care
All patients received sargramostim 250 mg/m2/day i.v. from day 0 until
a WBC count of >300  109/L was measured on 2 days, and were then
switched to either i.v. or s.c. ﬁlgrastim (10 mg/kg/day) until an ANC of 2500
109/L was measured on 3 days, as described previously [21]. Herpes simplex
virus prophylaxis consisted of acyclovir 250 mg/m2 i.v. every 8 hours from
day 5 until engraftment and development of grade II mucositis. Pneumo-
cystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole up to
day 2 and then 3 times weekly after myeloid engraftment. Patients unable
to tolerate trimethoprim/sulfamethoxazole received i.v. pentamidine every
Table 1
Demographic Data for Pediatric RTC Allo-HSCT Recipients
Parameter All (n ¼ 100) MSD/MUD allo-HSCT (n ¼ 49) UCBT (n ¼ 51) P Value
Age, years, mean  SD 9.24  6.79 11.01  6.19 7.54  6.97 .010
Sex, n (%) .926
Male 71 (71) 35 (71.4) 36 (70.6)
Female 29 (29) 14 (28.6) 15 (29.4)
Follow-up, days, mean  SD 1329.01  1060.9 1404.3  1006 1256.6  1116.3 .489
Diseases, n (%) .317
Malignant 50 (50) 27 (55.1) 23 (45.1)
Nonmalignant 50 (50) 22 (44.9) 28 (54.9)
Disease status, n (%) .030
Average risk 89 (89) 47 (95.9) 42 (82.4)
Poor risk 11 (11) 2 (4.1) 9 (17.6)
Previous autologous SCT, n (%) .281
No 77 (77) 40 (81.6) 37 (72.6)
Yes 23 (23) 9 (18.4) 14 (27.4)
Chemotherapy-naivety, n (%) .865
Yes 58 (58) 28 (57.1) 30 (58.8)
No 42 (42) 21 (42.9) 21 (41.2)
CMV status, n (%) .864
High 58 (58) 29 (59.2) 29 (56.9)
Intermediate 12 (12) 5 (10.2) 7 (13.7)
Low 30 (30) 15 (30.6) 15 (29.4)
Major ABO incompatibility, n (%) .390
Yes 22 (22) 9 (18.4) 13 (25.5)
No 78 (78) 40 (81.6) 38 (74.5)
Regimen, n (%) .433
Bu/Flu/alemtuzumab 35 (35) 20 (40.8) 15 (29.4)
Bu/Flu  r-ATG 45 (45) 21 (42.9) 24 (47.1)
Flu/Cy  r-ATG 20 (20) 8 (16.3) 12 (23.5)
Performance status, n (%) .015
Pre-RTC allo-HSCT >70 85 (85) 46 (93.4) 39 (76.5)
70 15 (15) 3 (6.6) 12 (23.5)
Bu indicates busulfan; Flu, ﬂudarabine; Cy, cyclophosphamide; r-ATG, rabbit antithymocyte globulin.
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day i.v. starting on day 0 and continuing through day þ100, as described
previously [22]. Cytomegalovirus (CMV) prophylaxis was administered as
described previously [23]. In brief, allo-HSCT recipients at risk of acquiring
CMV infection (CMV-positive donors and/or recipients) after achieving an
ANC>750 109/L received prophylaxis with foscarnet 90 mg/kg/dose every
other day, alternating with ganciclovir 5 mg/kg/dose every other day up to
day þ100.
Deﬁnitions
Major ABO incompatibility was deﬁned as donor blood type A, AB, or B
and recipient blood type O. CMV risk status was considered high if only the
recipient or the donor was CMV-positive, intermediate if both the recipient
and donor were CMV-positive, and low if both the recipient and donor were
CMV-negative. PGF was deﬁned as failure to achieve a donor-derived ANC
>500  109/L by day þ42 and/or 50% whole blood donor chimerism by
day þ60 in all patients except those with immune deﬁciency. In patients
with T cell or combined immune deﬁciency, PGF was deﬁned as 50% T cell
(CD3) donor chimerism by day þ180. Patients who had received a second
stem cell infusion before day þ42 for impending graft failure were also
considered to have PGF. CMV and adenovirus disease were deﬁned as
described previously [24]. TRM was deﬁned as death due to any
transplantation-related cause other than disease relapse.
Event-free survival (EFS) for patients with malignant disease was
deﬁned as relapse/persistence of the disease and death due to any cause
other than disease relapse. EFS for nonmalignant diseases was deﬁned as
persistence of disease, graft failure, and death due to any cause. OS was
deﬁned as survival with or without the original disease. Disease-free
survival (DFS) for patients with malignant disease was deﬁned as survival
without the original disease.
Poor-risk patients were deﬁned as patients with malignant disease and
either chemotherapy-resistant disease in third or greater complete remis-
sion (CR), with induction failure, or progressive disease. All other patients
with malignant and nonmalignant diseases were deﬁned as average risk.
Statistical Methods
The continuous variables were summarized as mean  standard devi-
ation, and categorical variables were summarized as percentages. The
Kaplan-Meier product limit estimator was used for estimating OS and PGF.
The probabilities of EFS, TRM, aGVHD, cGVHD, neutrophil recovery, and
platelet recovery were estimated by the cumulative incidence functionestimator. The competing risk for TRM was disease relapse, and the
competing risk for relapse was TRM. The cause-speciﬁc proportional
hazards model was used to analyze TRM. For aGVHD and cGVHD, death
without an event, relapse, and PGF were competing risks. The competing
risk for neutrophil and platelet recovery was death before recovery. In OS
and EFS analysis, PGF was treated as a time-dependent covariate. The esti-
mated probabilities were summarized along with standard error of the
mean. The log-rank test was used to assess the difference in these proba-
bilities among different groups. The Cox proportional hazards model was
used to adjust risk factors.
In univariate analysis for OS and TRM, risk factors analyzed included age,
sex, donor stem cell source, disease status, disease type, chemotherapy-
naivety, CMV risk status, ABO incompatibility, regimen received, perfor-
mance status, infection (viral, bacterial, and fungal), previous autologous
HSCT, PGF, aGVHD and cGVHD, percent donor chimerism, infused total
nucleated cell (TNC) dose, and infused CD34 cell dose.
In univariate analysis for OS in UCBT recipients who developed PGF, risk
factors analyzed included age, sex, disease status, disease type,
chemotherapy-naivety, CMV risk status, ABO incompatibility, regimen
received, infections (viral, bacterial, and fungal), infused TNC dose (5
versus>5107/kg), and infused CD34 cell dose (1.7 versus>1.7 105/kg).
Any covariates with a P value <.20 on univariate analysis were included in
the multivariate analysis.
RESULTS
Demographic Data
We prospectively evaluated 100 consecutive patients
enrolled in our RTC allo-HSCT protocols (Table 1). Therewere
71 males and 29 females; with a mean  standard deviation
(SD) age of 9.24  6.79 years. The mean follow-up duration
was 1329.01  1060.9 days. Fifty patients had malignant
disease, and 50 patients had nonmalignant disease. The
distribution of malignant diseases included 14 patients with
AML (10 in CR1 and 4 in CR2), 4 with MDS, 6 with chronic
phase CML, 7 with relapsed non-Hodgkin lymphoma, 9 with
relapsed/refractory Hodgkin lymphoma, and 10 with high-
risk neuroblastoma. The distribution of nonmalignant
diseases included 23 patients with hemoglobinopathies, 10
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trophies, and 5 with other diseases. Twenty-three patients
with lymphoma and neuroblastoma underwent planned
MAC autologous HSCT before RTC allo-HSCT as required by
their speciﬁc clinical research trial. Eleven patients (11%) had
poor-risk disease. Fifty-eight patients were chemotherapy-
naive, and 42 patients had received previous chemo-
therapy. A major blood group mismatch was noted in 22
donorerecipient pairs. Thirty donorerecipient pairs were
CMV-negative and 70 patients, either donor or recipient or
both, were CMV-positive. Fifteen patients (15%) had a Lansky
or Karnofsky score of70,12 patients (12%) had a score of 80,
and 73 patients (73%) had a score of 90-100 (Table 1).Donor Sources, Hematopoietic Reconstitution, and Donor
Chimerism
Forty-one patients received allogeneic hematopoietic
stem cells from a 5-6/6 HLA-matched family donor (HLA
matching, 33 6/6 sibling donors, 7 5/6 sibling donors, and 16/
6 maternal donor). Eight patients received an MUD graft
(HLA matching, 2 8/10, 5 9/10, and 1 10/10). Twenty-four of
the 49 patients who underwent MSD/MUD allo-HSCT had
a malignant disease; 18 of these patients received PBSCs, and
the other 6 received BM infusions. All 25 MSD/MUD allo-
HSCT recipients with nonmalignant disease received BM
infusions. Fifty-one patients underwent single-unit UCBT
(HLA matching, 25 4/6, 20 5/6, and 6 6/6). Median TNC and
CD34 cell doses infused in MRD graft recipients were 10.9 
107/kg (range, 0.9  107-189.7  107) and 5  106/kg (range,
0.2-16.4  106), respectively. Median TNC and CD34 cell
doses infused in UCBT recipients were 5.0  107/kg (range,
0.9  107-42  107) and 2.5  105/kg (range, 0.3  105-9.6 
105), respectively. Median TNC and CD34 cell doses infused in
MUD graft recipients were 76.2  107/kg (range, 3.4  107-
189.7  107) and 5  106/kg (range, 2.1  105-16.4  106),
respectively. Mean  SD values are presented in Table 2.
The cumulative incidence of neutrophil engraftment was
98% (95% CI, 92.9%-100%) in MSD/MUD graft recipients and
70.6% (95% CI, 57.8%-83.4%) in UCBT recipients. The cumu-
lative incidence of platelet engraftment was 89.8% (95% CI,
80.8%-98.8%) inMSD/MUD graft recipients and 58.8% (95% CI,
45.0%-72.6%) in UCBT recipients. In the patients who
engrafted (n ¼ 84), the median time to neutrophil engraft-
ment was 18 days (Figure 1A), and the median time to
platelet engraftment was 43 days (Figure 1B). The median
times to neutrophil and platelet engraftment after MSD/
MUD allo-HSCTwere 15 days (95% CI,14-17 days) and 18 days
(95% CI, 15-27 days), respectively. The median times to
neutrophil and platelet engraftment after UCBT were 32 daysTable 2
Allogeneic Donor Sources, HLA Disparity, and Cell Dose in Pediatric RTC Allo-
HSCT Recipients
Parameter All MSD/MUD
allo-HSCT
UCBT P Value
HLA match, n (%) <.0001
4/6 25 (25) 0 (0) 25 (49.0)
5/6 27 (27) 7 (14.3) 20 (39.2)
6/6 40 (40) 34 (69.4) 6 (11.8)
8-9/10 7 (7) 7 (14.3) 0 (0)
10/10 1 (1) 1 (2.0) 0 (0)
TNC dose, 107/kg,
mean  SD
40.4  47.4 75.1  46.0 6.5  6.4 <.0001
CD34 cell dose,
105/kg,
mean  SD
26.4  32.3 50.0  31.1 2.8  2.0 <.0001(95% CI, 27-45 days) and 79 days (95% CI, 56-171 days),
respectively. There were no statistically signiﬁcant differ-
ences in donor chimerism values; median (range) donor
chimerism for engrafted UCBT recipients was 91% (1%-100%)
on day þ30, 98% (14%-100%) on day þ100, and 98% (55%-
100%) on day þ365, whereas median donor chimerism for
MSD/MUD allo-HSCT recipients was 99% (35%-100%) on
dayþ30, 99% (40%-100%) on dayþ100, and 100% (75%-100%)
on day þ365 (Figure 1C).
PGF
PGF occurred in 16 patients (16%) after RTC allo-HSCT,
with all cases occurring in UCBT recipients and none in
MUD/MSD graft recipients (31.4% versus 0%; P < .0001). The
incidence of PGF in UCBT recipients who were
chemotherapy-naive versus those who were not
chemotherapy-naive was 46.7% (14/30) versus 9.5% (2/21)
(P ¼ .019). Among the 51 UCBT recipients, the incidence of
PGF was 54% (6 of 11) with the FCA regimen, 16% (4 of 24)
with the BFA regimen, and 37% (6 of 16) with the BFC
regimen (Table 3). PGF was noted in 12 of 50 patients (24%)
with nonmalignant disease and in 4 of 50 patients (8%) with
malignant disease. Of the 29 UCBT recipients with nonma-
lignant disease, 12 (41%) developed PGF, including 6 of 16
(37%) with the BFC regimen, 6 of 11 (54%) with the FCA
regimen, and 0 of 2 with the BFA regimen. The distribution of
PGF was 5 hemoglobinopathies, 2 hemophagocytic lym-
phohistiocytosis, 3 AML/MDS, 1 recessive dystrophic epi-
dermolysis bullosa, 1 scleroderma, 1 CML, 1 mitochondrial
neurogastrointestinal encephalomyopathy, 1 PID, and 1
Wiskott-Aldrich syndrome; 8 of 16 patients with PGF are
alive.
We performed univariate analysis for various risk factors
associated with PGF after UCBT. Only chemotherapy-naivety
(hazard ratio [HR], 5.19; 95% CI, 1.18-22.89; P ¼ .030) was
a signiﬁcant risk factor for PGF. Nonmalignant disease
trended as a risk factor for PGF (P ¼ .077). However, disease
risk status (P ¼ .30), CMV and adenovirus infection (P ¼ .40),
TNC dose (P ¼ .60), and CD34þ cell dose (P ¼ .70) were not
signiﬁcant for the risk of developing PGF. However, on
multivariate analysis, neither disease type (P ¼ .90; HR, 0.9;
95% CI, 0.2-3.6) nor chemotherapy-naivety (P ¼ .10; HR, 3.9;
95% CI, 0.6-23.6) was signiﬁcantly associated with PGF.
aGVHD and cGVHD
The probability of grade II-IV aGVHD in the engrafted
cohort was 20% (95% CI, 12.1%-27.9%), and was 24.5% (95% CI,
12.3%-36.7%) in MSD/MUD graft recipients versus 15.7% (95%
CI, 5.6%-25.8%) in UCBT recipients (P ¼ .36) (Figure 2A). The
probability of cGVHD in the engrafted cohort was 13.5% (95%
CI, 6.6%-20.4%), and was 21.4% (95% CI, 9.4%-33.4%) in MSD/
MUD graft recipients versus 6.1% (95% CI, 0%-12.97%) in UCBT
recipients (P ¼ .024) (Figure 2B).
TRM
TRMwas 3% (95% CI, 0%-6.4%) by dayþ100 and 13.6% (95%
CI, 6.7%-20.5%) for the entrire study period (Figure 3). For the
entire study period, TRM was 8.4% (95% CI, 0.4%-16.4%) for
patients with malignant disease and 18.8% (95% CI,
7.5%-30.0%) for patients with nonmalignant disease. Causes
of TRM in the ﬁrst 100 days included viral infections (n ¼ 2)
and veno-occlusive disease (VOD; n ¼ 1). Over the entire
study period, 11 patients died due to TRM; these deaths were
related to viral infection (n¼ 4), GVHD (n¼ 2), complications
related to second allo-HSCT in patients with PGF (n ¼ 3),
Figure 1. (A and B) Probability of neutrophil engraftment (A) and platelet engraftment (B) after RTC allo-HSCT in children and adolescents with malignant and
nonmalignant diseases. (C) Percent donor chimerism (mean  SD) after RTC allo-HSCT in engrafted children and adolescents with malignant and nonmalignant
diseases.
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(n ¼ 1), and VOD (n ¼ 1). The vast majority of TRM
(10 of 11 cases) occurred within the ﬁrst year after RTC allo-
HSCT. Various risk factors associated with TRM were
analyzed with competing-risk regression analysis, with
relapse as a competing event. In the univariate analysis, risk
factors with a P  .20 included male sex (P ¼ .17),
chemotherapy-naivety (P ¼ .12), disease type (P ¼ .11), high
CMV risk status (P ¼ .18), ﬂudarabine/cyclophosphamideTable 3
Characteristics and Outcomes of Children with PGF after RTC Allo-HSCT with UCB
Patient Age, Years Diagnosis Chemotherapy-
Naive
Regimen TNC,
107/kg
CD34
105/k
1 1 b-thalassemia Yes FCA 9.5 3.69
2 14 CML Yes BFA 1.26 0.77
3 15 HLH No FCA 1.4 0.34
4 1 MDS Yes BFA 7.99 2.88
5 1 HLH No FCA 5.88 2.55
6 3 AML No BFA 3.96 2.68
7 2 WAS Yes FCA 4.97 3.65
8 21 MNGIE Yes FCA 3.02 0.62
9 16 MDS Yes BFA 1.7 0.57
10 1 SCD Yes BFC 4.3 2.58
11 10 Scleroderma Yes BFC 4.8 4.18
12 2 SCD Yes BFC 6.95 2.09
13 6 SCD Yes BFC 3.9 1.9
14 0.6 PID Yes FCA 15.2 17
15 2 SCD Yes BFC 5.34 0.6
16 1 RDEB Yes BFC 12.48 3.28
HLH indicates hemophagocytic lymphohistiocytocis; WAS, Wiskott-Aldrich synd
sickle cell disease; RDEB, recessive dystrophic epidermolysis bullosa; FCA, ﬂudara
antithymocyte globulin; BFC, busulfan/ﬂudarabine/Campath; NED, no evidence ofregimen (P ¼ .082), and PGF (P ¼ .002). However, in the
multivariate analysis of TRM using variables signiﬁcant at
.20 from the univariate analysis, only PGF (relative risk,
3.92; 95% CI, 1.353-11.36; P ¼ .012) was signiﬁcantly associ-
ated with TRM (Table 4).
Survival after RTC Allo-HSCT
The 5-year EFS for the entire cohort was 59.5%  5% (95%
CI, 50.1%-70.6%) (Figure 4A), and was 78.2% (67.1%-91.2%) in,
g
Probable Cause
of PGF
Autologous
Recovery
Outcome
Unknown Yes Alive after MAC UCBT (day þ3294)
Unknown Yes Lost to follow-up
Unknown Yes Alive, NED (day þ2929)
Unknown Yes Alive after MAC UCBT (day þ2864)
Unknown Yes Alive after MAC UCBT (day þ2771)
Disease Yes Died, progressive disease
Unknown No Died after second RTC UCBT
Unknown Yes Died, progressive disease
Unknown No Died due to bacterial infection
Unknown Yes Alive with disease (day þ1797)
CMV Yes Alive with disease (day þ1222)
CMV Yes Died due to CMV
CMV No Died after second MAC-MUD
Unknown Yes Alive after MAC UCBT (day þ766)
Adenovirus No Died after second RTC UCBT
Strenotrophomonas
infection
No Died after second RTC UCBT (VOD)
rome; MNGIE, mitochondrial neurogastrointestinal encephalopathy; SCD,
bine/cyclophosphamide/antithymocyte globulin; BFA, busulfan/ﬂudarabine/
disease.
Figure 2. Probability of grade II-IV aGVHD (A) and cGVHD (B) after RTC allo-HSCT in children and adolescents with malignant and nonmalignant diseases.
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29.3%-59.2%) in UCBT recipients (P < .0001). The 5-year OS
for the entire cohort was 72.9% (95% CI, 64.2%-82.8%), and
was 84.3% (95% CI, 74.2%-95.8%) in MSD/MUD RTC allo-HSCT
recipients versus 62.0% (95% CI, 49.3%-78.1%) in UCBT
recipients (P < .0001), respectively (Figure 4B).
All of the surviving patients with malignant diseases had
more than 1 year of follow-up. Twenty-ﬁve patients received
RTC allo-HSCT in CR,19 remain in CR, 5 relapsed (died), and 1
experienced TRM. Twenty-ﬁve patients underwent RTC allo-
HSCT without achieving CR, 11 relapsed (8 died, 2 are alive,
and 1 was lost to follow-up), 10 achieved CR, and 4 experi-
enced TRM. Our patients who underwent RTC allo-HSCT for
malignant disease had a 32% incidence of relapse, a TRM of
10%, an OS of 64%, and a DFS of 58%.
In our multivariate analysis of risk factors associated with
OS, only poor-risk disease status (HR, 3.73; 95% CI, 1.2-11.5;
P ¼ .02), intermediate CMV risk status (HR, 5.6; 95% CI,
1.4-22.33; P ¼ .01), and PGF (HR, 4.06; 95% CI, 1.39-11.81;
P ¼ .01) were associated with signiﬁcantly worse OS
(Table 5). Because RTC UCBT was associated with a signiﬁ-
cantly poorer OS compared with MUD/MSD allo-HSCT, we
further analyzed various risk factors that could be associated
with poor OS in children after RTC UCBT. Risk factors in
the univariate analysis with P  .20 included age (P ¼ .09),
poor-risk disease (P ¼ .002), malignant disease (P ¼ .18),Figure 3. Probability of TRM after RTC allo-HSCT in children and adolescents
with malignant and nonmalignant diseases.intermediate CMV risk status (P ¼ .138), and PGF (P ¼ .038).
In the multivariate analysis of OS in children receiving RTC
UCBT, only poor-risk disease status (HR, 5.96; 95% CI, 1.57-
22.54; P¼ .009), intermediate CMV risk status (HR, 4.92; 95%
CI, 1.09-22.26), and PGF (HR, 4.54; 95% CI, 1.49-13.79) were
signiﬁcantly associated with decreased OS (Table 6).
DISCUSSION
Here we report the largest study to date of RTC allo-HSCT
using both related and unrelated allogeneic stem cell sources
in pediatric recipients with both malignant and nonmalig-
nant diseases. In the last several years, the use of RTC allo-
HSCT has expanded from adults with high comorbidity
indices to adult allo-HSCT candidates without comorbidities
[25,26]. The notion is prevalent that because children usually
do not have the comorbidities typical of adults (eg, chronic
hypertension, diabetes mellitus, chronic coronary ischemic
disease, smoking-related illnesses), they can tolerate MAC.
However, heavily pretreated children are at risk for early
TRM and long-term morbidities. A recently published
multicenter retrospective study analyzed the impact of an
allo-HSCTespeciﬁc comorbidity index (HCT-CI) on TRM in
children with malignant and nonmalignant diseases. Chil-
dren with an HCT-CI score of 3þ had a 1-year TRM of 36%
after MAC allo-HSCT and 19% after reduced-intensity/non-Table 4
Multivariate Competing-Risk Analysis of TRM with Variables Signiﬁcant at
P  .20 in Univariate Analysis in Pediatric RTC Allo-HSCT Recipients
Parameter RR 95% CI P Value
Sex
Male (n ¼ 71) 1
Female (n ¼ 29) 1.70 0.442-6.53 .440
Diseases
Nonmalignant (n ¼ 50) 1
Malignant (n ¼ 50) 0.59 0.155-2.25 .440
Chemotherapy-naive
No (n ¼ 42)
Yes (n ¼ 58) 1.96 0.408-9.38 .400
CMV risk status
Low (n ¼ 32) 1
High (n ¼ 58) 2.88 0.545-15.28 .210
Intermediate (n ¼ 12) 1.24 0.059-25.97 .890
Regimen
Bu/Flu/r-ATG (n ¼ 45) 1
Bu/Flu/alemtuzumab (n ¼ 35) 1.01 0.264-3.89 .980
Flu/Cy/r-ATG (n ¼ 20) 1.44 0.297-7.00 .650
PGF
No (n ¼ 84) 1
Yes (n ¼ 16) 3.92 1.353-11.36 .012
Bu indicates busulfan; Flu, ﬂudarabine; r-ATG, rabbit antithymocyte glob-
ulin; Cy, cyclophosphamide; RR, relative risk.
Figure 4. EFS (A) and OS (B) after RTC allo-HSCT in children and adolescents with malignant and nonmalignant diseases.
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a 60- to 70-year life expectancy after undergoing allo-HSCT
may beneﬁt from the approach of RTC allo-HSCT versus
MAC allo-HSCT, especially those with nonmalignant diseases
and those with malignant diseases that may have a profound
graft-versus-tumor effect [28-30].
TRM is a major concern after allo-HSCT. Several small
pediatric studies have reported TRM of 13%-40% after RTC
allo-HSCT [14,15,31-33]. However, Jacobsohn et al. [15] re-
ported a 15% dayþ100 TRM in children undergoing RTC allo-
HSCT for nonmalignant disease. One of the most important
ﬁndings in the present analysis was the extremely low
probability of TRM both at day þ100 (3%) and in the entire
study period (13.6%). Only 3 patients experienced TRM
within the ﬁrst 100 days after RTC allo-HSCT, including 2
patients who died of systemic viral infection (SVI) and 1Table 5
Multivariate Analysis of OS with Variables Signiﬁcant at P .20 in Univariate
Analysis
Parameter HR 95% CI P Value
Age 1.045 0.976-1.119 .203
Donor
MSD (n ¼ 41) 1
MUD (n ¼ 8) 0.593 0.064-5.523 .646
UCB (n ¼ 51) 1.288 0.416-3.984 .661
Disease risk status
Average (n ¼ 89) 1
Poor (n ¼ 11) 3.731 1.206-11.542 .022
CMV risk status
Low (n ¼ 30) 1
Intermediate (n ¼ 12) 5.614 1.411-22.338 .014
High (n ¼ 58) 2.936 0.858-10.049 .086
Regimen
Bu/Flu  r-ATG (n ¼ 45) 1
Bu/Flu/alemtuzumab (n ¼ 35) 0.926 0.353-2.426 .875
Flu/Cy  r-ATG (n ¼ 20) 0.675 0.189-2.407 .545
Performance status
>70 (n ¼ 85) 1
<70 (n ¼ 15) 1.247 0.318-4.890 .752
Fungal infection
No (n ¼ 92) 1
Yes (n ¼ 8) 2.094 0.550-7.968 .278
PGF
No (n ¼ 84) 1
Yes (n ¼ 16) 4.058 1.393-11.817 .010
Bu indicates busulfan; Flu, ﬂudarabine; r-ATG, rabbit antithymocyte glob-
ulin; Cy, cyclophosphamide.patient who died of severe VOD. We previously analyzed the
incidence of both viral and fungal infections in pediatric RTC
allo-HSCT and MAC allo-HSCT recipients, but were unable
to demonstrate a signiﬁcant reduction in the incidence of
SVI in the RTC allo-HSCT recipients [24]. This ﬁnding is
related in part to our previous report demonstrating no
signiﬁcant differences in T cell immune reconstitution,
especially after UCBT, in pediatric RTC allo-HSCT and MAC
allo-HSCT recipients [34,35]. More important, the reported
TRM in pediatric MAC allo-HSCT recipients is 5%-20% when
using HLA-matched related donors and 10%-50% when using
unrelated donors, particularly unrelated UBC [8,10,11,36].
Our ﬁnding of a TRM of only 3% in the ﬁrst 100 days after
RTC allo-HSCT, even with 50% of the patients receiving UBC
grafts, represents a dramatic improvement over MAC allo-
HSCT in the pediatric population. Jacobsohn et al. [15] re-
ported a day þ100 TRM of 15% in children undergoing RTC
allo-HSCT for nonmalignant disease.
In the present analysis, the median time to myeloid and
platelet engraftment after RTC allo-HSCT in pediatric recip-
ients was 18 and 43 days, respectively, consistent with
reports after MAC allo-HSCT. Most important, in patients
who achieved donor engraftment, both early (day 30-100)
and late (1 year) donor chimerismwere robust, ranging from
95% to 98%. This long-term high-level donor chimerism after
RTC allo-HSCT was remarkable and also consistent with
reports after MAC allo-HSCT, suggesting that despite the useTable 6
Multivariate Analysis of OS in Children after RTC Allo-HSCT with UCB
(n ¼ 51) with Variables Signiﬁcant at P  .20 in Univariate Analysis
Parameter HR 95% CI P Value
Age 1.024 0.941-1.114 .589
Disease risk status
Average risk (n ¼ 42) 1
Poor risk (n ¼ 9) 5.957 1.574-22.541 .009
Disease type
Nonmalignant (n ¼ 30) 1
Malignant (n ¼ 21) 1.035 0.249-4.298 .963
CMV risk status
Low (n ¼ 15) 1
High (n ¼ 28) 2.009 0.604-6.685 .255
Intermediate (n ¼ 8) 4.642 1.019-21.139 .047
PGF
No 1
Yes 4.538 1.494-13.786 .008
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high-level donor chimerism is persistent in pediatric RTC
allo-HSCT recipients. These long-term donor chimerism
results are consistent with previous smaller studies of
pediatric RTC allo-HSCT recipients from our group and other
groups [3,14-17,37-39].
The higher-than-expected incidence of PGF (16%) in the
present study appeared to be concentrated in the subgroup
of RTC UCBT recipients. No PGF was seen in the RTC MSD/
MUD allo-HSCT recipients. These ﬁndings are in contrast to
the results of studies reporting anw33% incidence of PGF in
a subgroup of RTC UCBT recipients, which were 1-1.5 times
higher than that in MAC UCBT recipients [38,40]. The risk of
PGF was signiﬁcantly higher in the chemotherapy-naive RTC
recipients comparedwith the nonechemotherapy-naive RTC
UCBT recipients. On multivariate analysis, chemotherapy-
naivety was not signiﬁcantly associated with PGF, likely
owing to the small number of patients; however, the HR was
3.9. The 10% incidence of PGF in our nonechemotherapy-
naive RTC UCBT recipients is similar to the incidence re-
ported in pediatric MAC UCBT recipients. The majority of
cases of PGF after RTC UCBT occurred in children with
hemoglobinopathies and other nonmalignant conditions, in
agreement with previous reports [30,37,38,41]. These
patients with PGF and the RTC UCBT recipients were treated
on different studies, and owing to the small numbers of graft
failures in each study stopping criteria to perform UCBTwere
not met. However, when we compiled data from all of these
studies, we deemed the graft failure rates unacceptable.
Thus, we no longer perform RTC UCBT for patients with
chemotherapy-naive diseases at our center. Several factors
are likely associated with the high incidence of PGF in the
chemotherapy-naive RTC UCBT recipients, including 1 log
lower TNC and CD34 doses, reduced myeloablation, history
of blood cellesensitizing transfusions, and primary BM
disorders, among others; these factors alone or in combina-
tion may lead to a increased incidence of PGF after RTC UCBT
in pediatric recipients with nonmalignant disease. The
optimal RTC regimen before UCBT that will be associated
with donor engraftment is unclear. In the present study, the
incidence of PGF was identical after the FCA regimen and
after the more-intense BFC regimen. Future studies of RTC
should explore alternative RTC conditioning regimens to
increase the incidence of donor engraftment after UCBT.
We did not notice any PGF in MSD/MUD alloHSCT recip-
ients, and thus did not further analyze differences in the risk
of PGF in recipients of BM infusions and recipients of PBSC
infusions. However, in a prospective study of 47 children
with malignant diseases, PGF was reported in patients who
received a BM infusion after RTC [16].
The probability of grade II-IV aGVHD in our pediatric RTC
allo-HSCT recipients was only 20%, which was lower than
what would have been predicted in MAC allo-HSCT recipi-
ents. This lower incidence of grade II-IV aGVHD in pediatric
RTC allo-HSCT recipients is similar to what has been
described in adults after either reduced-intensity condi-
tioning or RTC allo-HSCT [42-44]. Several factors likely
account for this lower incidence of grade II-IV aGVHD after
RTC allo-HSCT, including decreased acute tissue damage
after RTC allo-HSCT and transient and slower donor chime-
rism early after allo-HSCT, which may promote hostedonor
tolerance, thereby reducing early aGVHD [29]. The 13% inci-
dence of cGVHD in the present study is largely consistent
with the incidence after MAC UCBT reported previously
[7,10,16,35,36,40,45].The probability of OS in RTC allo-HSCT recipients was 72%,
and was signiﬁcantly higher in MSD/MUD graft recipients
compared with UCBT recipients (84% versus 62%). This
probability is similar to or, in some instances, improved over
previously reported values in pediatric MAC allo-HSCT
recipients [8,10,36]. In a multivariate analysis of risk factors
associated with poor OS in RTC allo-HSCT recipients, poor-
risk disease status and intermediate CMV risk were associ-
ated with signiﬁcantly poorer OS. Why CMV intermediate
risk status is associated with poor OS is not clear, given that
these patients receive similar CMV prophylaxis as patients
with high-risk CMV status. Only 3 of the 11 cases of TRM in
the study population can be attributed to PGF, related in
part to the RTC regimen. The other 8 deaths (4 due to SVI, 2
due to GVHD,1 due to transplantation-associated thrombotic
microangiopathy, and 1 due to VOD) are all related to known
complications after allo-HSCT, and especially after MAC. The
excellent 5-year OS after RTC allo-HSCT in our pediatric
recipients with malignant and nonmalignant disease is
encouraging, but await conﬁrmation in a larger and more
uniform cohort.
The presence of measurable disease at the time of RTC
allo-HSCT affects outcome. Pulsipher et al. [14] reported DFS
of 75% in patients who underwent RTC allo-HSCT in CR,
compared with 17% in those who underwent RTC allo-HSCT
without achieving CR [14]. In our series, patients under-
going RTC allo-HCST in CR had a DFS of 76%, compared with
40% in those who did not achieve CR. Efforts should focus on
achieving CR before RTC allo-HSCT, to decrease the risk of
relapse. If this is not possible, then MAC allo-HSCT should be
performed if clinically feasible.
This study has several limitations that should be consid-
ered when interpreting our results. The patient population
was heterogeneous in terms of diseases, disease status, and
history of previous chemotherapy. In addition, the allogeneic
donor sources were heterogeneous and included HLA MSDs,
MUDs, and UBC. The RTC regimens varied somewhat, but
were all ﬂudarabine-based; 80% included busulfan, and 20%
included cyclophosphamide, and the majority included
either r-ATG or alemtuzumab. The analyses were performed
retrospectively, and there was no concurrent MAC allo-HSCT
cohort. Nonetheless, GVHD prophylaxis and supportive care
were uniform in all patients, and the heterogeneity of the
patients and donor sources allows for more generalizability
across pediatric RTC allo-HSCT recipients. Another limitation
of this study is that although theoretically RTC allo-HSCT
should be associated with reduced long-term toxicity, we
have no long-term data to support or refute this association.
In summary, this study represents the largest series of
pediatric RTC allo-HSCT recipients reported to date. The TRM
at day þ100 and for the entire study period (3% and 13.6%,
respectively) is lower than all previously reported series of
pediatric MAC and MUD allo-HSCT recipients. The low inci-
dence of grade II-IV aGVHD in our series contributed to this
low incidence of TRM, especially in terms of infection- and
GVHD-associated deaths. The 84% 5-year OS and absence of
PGF in our RTC MSD/MUD allo-HSCT recipients are encour-
aging. PGF was highly prevalent in the RTC UCBT recipients,
especially in the chemotherapy-naive recipients. This high
rate of PGF in our subgroup of chemotherapy-naive pediatric
patients with malignant (CML, MDS) and nonmalignant
diseases after RTC UCBT is unacceptable and should be the
subject of future investigations using such strategies as
increased immunoablation in RTC regimens, increased UCBT
cell doses, double UCBTs, ex vivo expanded UCBTs, and/or
P. Satwani et al. / Biol Blood Marrow Transplant 19 (2013) 552e561560pluripotent or mesenchymal stem cellular adjuvants to
promote increased engraftment. Future studies should
conﬁrm our preliminary results in larger andmore uniformly
deﬁned cohorts in prospective trials in pediatric RTC allo-
HSCT recipients.
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